seri
pyrazolon
compound
possibl
sarscov
proteas
inhibitor
design
synthes
evalu
vitro
proteas
assay
use
fluorogen
substrat
peptid
sever
show
potent
inhibit
proteas
interestingli
one
inhibitor
also
activ
proteas
coxsackieviru
inhibitor
could
potenti
develop
anticoronavir
antipicornavir
agent
sever
acut
respiratori
syndrom
sar
newli
emerg
infecti
diseas
caus
novel
coronaviru
sarscoronaviru
sarscov
sar
recogn
global
threat
sinc
initi
outbreak
sar
first
identifi
guangdong
provinc
china
novemb
outbreak
spread
sever
countri
signific
health
econom
impact
sar
lifethreaten
form
atyp
pneumonia
character
high
fever
malais
rigor
headach
chill
cough
progress
radiograph
chang
chest
lymphophenia
mortal
rate
nearli
sarscov
positivestrand
rna
viru
use
complex
set
enzym
replic
largest
rna
genom
current
known
rna
virus
synthes
extens
set
leadercontain
subgenom
mrna
encod
viral
structur
protein
sever
speciesspecif
protein
unknown
function
process
mediat
primarili
proteas
pro
chymotrypsin
fold
activ
site
sarscov
pro
contain
constitut
catalyt
dyad
cystein
function
common
nucleophil
proteolyt
process
essenti
role
viral
process
pro
consid
attract
target
antisar
coronaviru
infect
pro
name
proteas
pro
picornavirus
enteroviru
ev
coxsackieviru
cv
rhinoviru
rv
caus
lifethreaten
infecti
diseas
pro
essenti
viral
replic
serv
drug
target
pro
pro
similar
structur
unlik
dimer
pro
pro
monomer
util
gluhisci
triad
catalysi
date
variou
sarscov
proteas
inhibitor
report
screen
compound
librari
design
compound
base
substrat
structur
activ
site
properti
scaffold
divers
includ
c
symmetr
diol
acid
deriv
deriv
cinanserin
calmodulin
ketoglutamin
analog
anilid
bifunct
boron
acid
compound
isatin
deriv
pyrmidinon
benzotriazol
well
glutam
acid
glutamin
peptid
possess
trifluoromethyl
keton
group
bunsatur
ester
etacryn
acid
deriv
metalcoordin
structur
molecul
make
coval
bond
activ
site
sarscov
pro
howev
effect
therapi
develop
far
recent
isol
strain
sarscov
emphas
possibl
reemerg
therefor
still
great
challeng
explor
new
chemic
class
sarscov
pro
inhibitor
use
antisar
therapi
case
diseas
reemerg
compound
contain
pyrazol
relat
analog
receiv
signific
attent
chemic
medicin
pharmaceut
research
structur
scaffold
found
varieti
drug
shown
figur
new
pyrazolon
compound
edaravon
also
known
develop
medic
drug
brain
ischemia
also
report
effect
myocardi
ischemia
compound
b
claim
potent
antiorthopoxviru
activ
compound
c
report
sarscov
pro
inhibitor
recent
identifi
high
throughput
screen
certain
pyrazolin
particularli
display
substitut
pattern
activ
sarscov
pro
pro
pro
pro
pro
present
studi
synthes
pyrazolon
compound
sar
proteas
inhibitor
explor
structureact
relationship
sar
inhibit
pro
pro
view
fact
mention
compound
contain
pyrazolon
templat
synthes
screen
proteas
inhibitori
activ
synthes
compound
display
potent
inhibit
pro
sarscov
pro
synthesi
target
compound
envis
follow
synthet
rout
illustr
scheme
compound
synthes
reflux
correspond
bketoest
substitut
phenylhydrazin
hydrochlorid
acet
acid
pyrazolon
treat
appropri
aromat
aldehyd
presenc
piperidin
ethanol
obtain
target
compound
yield
preliminari
investig
summar
tabl
note
compound
substitu
r
carboxyl
group
posit
benzyliden
aryl
ring
show
signific
inhibit
sarscov
pro
compound
r
substitut
like
halogen
cyano
nitro
group
increas
inhibitori
action
see
tabl
compound
potent
inhibitor
show
ic
lm
second
ic
lm
pro
interestingli
show
inhibitori
activ
significantli
pro
ic
lm
pro
ic
lm
cytotox
test
compound
test
perform
mtt
assay
found
compound
devoid
cytotox
lm
search
comput
model
associ
complex
compound
proteas
ration
inhibitori
activ
orient
ligand
group
situat
pocket
pro
one
oxygen
nitro
group
close
proxim
form
hbond
fig
c
central
pyrazolon
ring
close
distanc
form
hbond
phenyl
ring
fit
pocket
hydrophob
interact
hide
behind
resid
fig
carboxyl
benzyliden
group
situat
pocket
pro
oxygen
carboxyl
group
form
hydrogen
bond
side
chain
distanc
piperidin
etoh
scheme
gener
synthesi
compound
import
inhibit
activ
sinc
compound
lack
carboxi
function
benzyliden
lost
activ
electron
withdraw
r
substitu
like
cyano
fluoro
nitro
accompani
r
carboxyl
group
favor
inhibitori
activ
evalu
inhibitor
pro
found
moder
inhibitor
pro
ic
lm
respect
activ
pro
ic
lm
accord
model
shown
figur
r
nitro
group
form
hbond
without
nitro
group
fail
form
hbond
benzyliden
carboxyl
hbond
activ
site
pro
predict
phenyl
ring
point
site
carboxyl
benzyliden
group
reloc
order
form
hbond
pro
due
subtl
differ
structur
pro
pro
howev
note
comput
model
specul
base
energi
minim
fit
sar
data
conclus
select
pro
common
inhibitor
pro
pro
may
potenti
develop
anticoronavir
antipicornavir
drug
report
pyrazolon
compound
aryl
ring
attach
pyrazolon
show
potent
pro
inhibit
group
attach
atom
gave
simultan
inhibitori
activ
pro
chemic
reagent
grade
use
purchas
sigmaaldrich
usa
acro
organ
co
ltd
usa
esitofm
spectra
record
bruker
biotof
ii
mass
spectromet
h
nmr
spectra
record
spectromet
tm
intern
standard
chemic
shift
report
ppm
adjust
rel
residu
solvent
peak
equimolar
solut
ethyl
benzoylacet
substitut
phenylhydrazin
hydrochlorid
treat
triethylamin
mixtur
stir
reflux
temperatur
h
solvent
remov
evapor
residu
extract
acoet
organ
phase
dri
anhydr
na
evapor
reduc
pressur
get
crude
solid
crude
product
recrystallis
methanol
yield
pure
pyrazolon
spectroscop
data
describ
detail
equimolar
pyrazolon
substitut
benzaldehyd
piperidin
ethanol
ml
reflux
h
excess
ethanol
evapor
residu
pour
water
solid
product
filter
dri
recrystal
methanol
spectroscop
data
synthes
compound
describ
detail
fluorogen
peptid
substrat
dabcylktsavl
qsgfrkmeedan
use
assay
pro
pro
activ
sarscov
pro
pro
prepar
previous
report
proteas
store
buffer
contain
mm
trishcl
ph
mm
nacl
mm
edta
mm
bme
mm
dtt
use
pro
activ
test
compound
perform
solut
contain
lm
sar
pro
lm
fluorogen
substrat
lm
test
compound
activ
assay
use
lm
pro
enhanc
fluoresc
reaction
buffer
mm
bistri
ph
monitor
nm
excit
nm
use
fluoresc
plate
reader
fluoroskan
ascent
thermolabsystem
helsinki
finland
compound
inhibit
proteas
activ
lm
select
next
assay
run
cell
viabil
determin
mtt
tetrazolium
bromid
use
vybrant
mtt
cell
prolifer
assay
kit
purchas
molecular
probe
usa
human
embryon
kidney
hek
cell
ml
seed
cultur
plate
contain
ml
minimum
essenti
medium
mem
gibico
invitrogen
ca
usa
supplement
fetal
bovin
serum
fb
gibico
cultur
co
cell
confluenc
densiti
treat
compound
design
concentr
h
incub
mtt
bromid
stock
solut
ad
well
convers
mtt
formazan
viabl
cell
perform
anoth
h
reaction
dmso
solut
ad
well
follow
remov
cultur
media
order
solubil
formazan
precipit
level
formazan
determin
optic
densiti
nm
use
elisa
reader
repres
cell
viabil
gain
molecular
insight
mode
inhibit
activ
compound
conduct
dock
studi
pro
activ
site
model
analysi
crystal
structur
sar
pro
complex
peptid
inhibitor
pdb
code
use
dock
process
perform
use
autom
liganddock
subprogram
discoveri
studio
model
sbd
accelri
inc
san
diego
ca
set
paramet
chosen
control
precis
oper
genet
algorithm
dock
run
carri
use
standard
default
set
grid
resolut
site
open
bind
site
select
defin
activ
site
caviti
